A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation

Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors

(2020) Juan Montoro et al.   BONE MARROW TRANSPLANTATION

Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation

(2020) Monzr M. Al Malki et al.   Blood Advances

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

(2019) Javier Bolaños-Meade et al.   Lancet Haematology

Lower GVHD and relapse risk in PTCy-based Haploidentical vs Matched Sibling Donor RIC Transplant for Hodgkin Lymphoma

(2019) Sairah Ahmed et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Randomized Multicenter Trial of Sirolimus vs. Prednisone as Initial Therapy for Standard Risk Acute GVHD: BMT CTN 1501

(2019) Joseph Pidala et al.   BLOOD

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

(2017) Asad Bashey et al.   JOURNAL OF CLINICAL ONCOLOGY

Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation

(2016) Nelli Bejanyan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil

(2016) Ivan S. Moiseev et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Severe Cytokine-Release Syndrome after T Cell–Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti–IL-6 Therapy Is Safe and Well Tolerated

(2016) Ramzi Abboud et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

(2016) M. Mielcarek et al.   BLOOD

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

(2016) M Mohty et al.   BONE MARROW TRANSPLANTATION

Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation

(2015) Nelli Bejanyan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells

(2015) Nicoletta Cieri et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

(2015) Madan H. Jagasia et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study

(2015) Mohamed L. Sorror et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

(2015) S. R. McCurdy et al.   BLOOD

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

(2015) S. O. Ciurea et al.   BLOOD

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

(2015) S. G. Holtan et al.   BLOOD

Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide

(2015) L Castagna et al.   BONE MARROW TRANSPLANTATION

Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update

(2015) A Bacigalupo et al.   BONE MARROW TRANSPLANTATION

Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Brief-Course Sirolimus Following Reduced-Intensity Peripheral Blood Stem Cell Transplantation

(2014) Scott R. Solomon et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide

(2014) Luca Castagna et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

(2014) C. Cutler et al.   BLOOD

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

(2014) J Peccatori et al.   LEUKEMIA

Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial

(2013) H. S. L. Jim et al.   HAEMATOLOGICA

T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation

(2013) Asad Bashey et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation

(2012) Stefan O. Ciurea et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation

(2012) J. Pidala et al.   HAEMATOLOGICA

Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors

(2012) Claudio Anasetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia

(2011) Stella Santarone et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

(2011) C. G. Brunstein et al.   BLOOD

Patient-Reported Outcomes for Acute Graft-versus-Host Disease Prevention and Treatment Trials

(2009) Stephanie J. Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

(2008) Leo Luznik et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION